Evidence map›Paper›PMID 32211581›Full record

ArticleJNCI cancer spectrum2020

Prospective Evaluation of Universal

Trisha S Emborgo, Donika Saporito, Kimberly I Muse, Angelica M Gutierrez Barrera, Jennifer K Litton, Karen H Lu, Banu K Arun

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JNCI cancer spectrum, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Prevalence ofMolecular and clinical oncology · 2021
    Article
  7. Therapeutic advances in medical oncology · 2020
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Trisha S EmborgoBreast and Ovarian Cancers Moon Shots Program, The University of Texas MD Anderson Cancer Center, 1155 Pressler Street, Houston, TX, USA.ORCID 0000-0002-2694-1808
Donika SaporitoClinical Cancer Genetics Program, The University of Texas MD Anderson Cancer Center, 1155 Pressler Street, Houston, TX, USA.
Kimberly I MuseBreast and Ovarian Cancers Moon Shots Program, The University of Texas MD Anderson Cancer Center, 1155 Pressler Street, Houston, TX, USA.ORCID 0000-0001-8952-0384
Angelica M Gutierrez BarreraDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1155 Pressler Street, Houston, TX, USA.
Jennifer K LittonDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1155 Pressler Street, Houston, TX, USA.
Karen H LuBreast and Ovarian Cancers Moon Shots Program, The University of Texas MD Anderson Cancer Center, 1155 Pressler Street, Houston, TX, USA.
Banu K ArunBreast and Ovarian Cancers Moon Shots Program, The University of Texas MD Anderson Cancer Center, 1155 Pressler Street, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLimited published literature exists on women with triple-negative breast cancer (TNBC) diagnosed over the age of 60 years with breast cancer gene (

methodsA prospective study of 395 women with TNBC underwent genetic counseling and 380 (96.2%) underwent clinical

resultsFifty-one of 380 (13.4%) women with TNBC who underwent clinical

conclusionsOur study does not support universal

Identifiers

PMID32211581
PMCPMC7083268
OpenAlexW3000845996

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.